ProMIS Neurosciences Inc (PMN)

[noretreat]

"We are pleased to offer this private placement designed to afford a cash runway well into 2020. Proceeds of the offering will support further development of our programs targeting Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease, each of which is the subject of ongoing partnering discussions with large biopharmaceutical companies," stated Dr. Elliot Goldstein, ProMIS President and CEO.

Each Unit will consist of one common share of the Company and one share purchase warrant of the Company (each a "Warrant"). Each Warrant will entitle the holder thereof to purchase one share at an exercise price of $0.35 per share at any time through the fifth anniversary of the offering.

[noretreat]

ProMIS Neurosciences Is ProMIS’ Alzheimer’s Antibody Better Than Biogen’s?

ProMIS advances ALS Program.  ProMIS Neurosciences yesterday announced it has generated antibody candidates for the treatment of neurodegenerative diseases known as amyotrophic lateral sclerosis and frontotemporal dementia. We believe this is a positive development as the company nears completion of preclinical development and prepares to start human clinical trials.

ProMIS' differentiation. ProMIS is developing a novel therapeutic approach targeting a distinctive molecular entity, known as toxic oligomers, which the scientific literature recognizes as the true culprits of neurodegenerative diseases such as ALS, FTD, Alzheimer’s and Parkinson’s diseases. In contrast, competitor Biogen’s aducanumab is targeting amyloid-beta plaques for the treatment of Alzheimer’s. ProMIS’ lead drug PMN310 does not bind amyloid-beta plaques.

Impact of Biogen’s news. In a reversal of fortunes, Biogen’s stock gained 25% over the last two trading sessions after the company announced that it plans to file for FDA approval of aducanumab for the treatment of Alzheimer’s. On March 21, 2019, Biogen’s stock lost 29% after the company discontinued two Phase III clinical trials on the use of aducanumab. In our view, the news is positive for the sector. However, we still believe that ProMIS’ PMN310 is a superior drug.

Reiterating Outperform Rating.  We believe ProMIS’s currently deflated share price does not reflect the potential of its lead drug PMN310 and versatility of its antibody platform technology. In our opinion, PMN310 has a unique mechanism of action targeting the true culprit of Alzheimer's disease, which makes it potentially superior to aducanumab. We are reiterating our Outperform rating and $1.00 target price on the stock.

Equity Research Cosme Ordonez, MD, Ph.D., Senior Life Sciences Analyst [phone] [e-mail]
Noble Capital Markets, Inc. Trading: [phone] Sales: [phone] www.noblecapitalmarkets.com

[noretreat]

Memorandum from Executive Chairman Eugene Williams:

https://promisneurosciences.com/wp-content/uploads/2019/10/final.chairmans-memorandum.Oct_.23.2019.pdf

[noretreat]

The white paper....

https://promisneurosciences.com/wp-content/uploads/2019/10/FinalWhite-Paper.aducanumab-analysis.-23-OCT-2019-FINAL.pdf

[Phoenix300]

Uptrend continues. ARFXF

[noretreat]

ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
PR NEWSWIRE 2:00 AM ET 10/24/2019

New resources detail positive impact of aducanumab pivotal trial results and recent progress of ProMIS pipeline programs

TORONTO and CAMBRIDGE, MA, Oct. 24, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. , a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has issued a memorandum, compiled by its Executive Chairman of the Board, that provides context for the company's recent program progress as well as a white paper analysis of Biogen's October 22, 2019 decision to submit its amyloid-beta (Aß)-targeting drug candidate, aducanumab for Alzheimer's disease (AD) to the U.S. Food and Drug administration (FDA) in early 2020. The new resources detail how each development demonstrates strong momentum across the company's preclinical programs.

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

On October 22, 2019, Biogen announced that the conclusions from aducanumab's interim analysis for futility, disclosed on March 21, 2019, were incorrect. Biogen also announced that analysis of additional trial data now indicates that aducanumab is effective in patients with longer term, high-dose exposure, and that they plan to file a marketing application with FDA early next year.

"We believe that over the coming months there will be a greater recognition of the likelihood that Biogen's aducanumab will be the first ever approved disease modifying therapy in Alzheimer's, although with a modest clinical benefit," said Eugene Williams, Executive Chairman, ProMIS Neurosciences(ARFXF). "It will change the thinking about amyloid generally, and more people will understand the growing body of scientific literature showing that the toxic oligomer of amyloid is the critical target. Selectivity for the toxic oligomer, as demonstrated preclinically with ProMIS' candidate antibody therapeutic PMN310, will increasingly be recognized as a critical differentiator, the basis of 'best in class'. Those expectations could be very positive for ProMIS."

In October 2019, the company announced significant progress on several of its antibody programs demonstrating the unique ability of its drug discovery and development platform to rapidly and cost-effectively discover, predict and validate antibody candidates that are highly selective for neurotoxic misfolded proteins. Each of these programs, briefly updated below, is the object of ongoing partnering discussions with several large pharmaceutical companies.

Parkinson's disease (PD) and Multiple System Atrophy (MSA)—preclinical in vitro studies, announced October 8, indicate that antibody candidates targeting toxic forms of alpha-synuclein, a root cause of PD and MSA, bind strongly to toxic alpha-synuclein aggregates derived from MSA-affected brain. The antibodies also protect cultured neurons from alpha-synuclein toxicity and spreading (propagation).


Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)—new data, announced October 22, show several antibody candidates demonstrate selectivity for toxic, misfolded intracellular aggregates of TDP-43, a root cause of ALS and FTD, with no binding to normal TDP-43 located in the cell nucleus.


Alzheimer's disease—new data, announced October 17, show several antibody candidates bind toxic forms of tau, a protein that can misfold and play a major role in disease progression. The antibodies also inhibit propagation of neurotoxic tau in a cellular model.

For access to the Chairman's Update please click on: http://bit.ly/ProMIS102319
The white paper is available by clicking on: http://bit.ly/ProMISWP102319

To learn more about the role of amyloid beta in Alzheimer's disease including evidence implicating the toxic oligomer, tune into Saving Minds, at iTunes or Spotify.

[noretreat]

No question. This is an opportunity to accumulate.

[Phoenix300]

ARFXF is undervalued now. A deal could be shepherded along sooner.

[noretreat]

"The momentum behind each of our programs is palpable," said Elliot Goldstein, MD, ProMIS Neurosciences(ARFXF) President and CEO. "In the past 30 days, we've announced data advancing our development programs selectively targeting toxic misfolded proteins for treatment of Alzheimer's and Parkinson's disease and Multiple System Atrophy (MSA), ALS and FTD. Yesterday, Biogen's decision to submit its amyloid-beta targeting drug candidate, aducanumab, for FDA approval signaled a milestone shift in the promise of next-generation amyloid-beta targeting drugs. Our lead program, PMN310, offers sniper-like precision for the toxic, misfolded form of amyloid beta, a key feature that offers important potential advantages compared to aducanumab. We will continue to support the patient community by advancing our programs, in particular PMN310 for Alzheimer's disease, leveraging our proprietary, drug discovery platform."

[Phoenix300]

I bet there was!! Some phones rang today.

[noretreat]

Lots of excitement today at Promis.

[Phoenix300]

Biogen Surges After Announcing Plans to Pursue Alzheimer's Drug Approval

[Phoenix300]

ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
Oct 08, 2019 08:15 am
Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy

TORONTO, Ontario and CAMBRIDGE, Mass. — October 8, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has identified several novel antibody candidates for Multiple System Atrophy (MSA), a severe, Parkinson’s-like disease caused by toxic, misfolded forms of the protein alpha-synuclein. The new antibody candidates join ProMIS’ strong pipeline of antibodies that demonstrate high selectivity for toxic misfolded proteins, implicated as a root cause of several neurodegenerative diseases, including Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (ALS).

Our preclinical in vitro studies indicate that antibody candidates targeting toxic forms of alpha-synuclein bind strongly to toxic alpha-synuclein aggregates derived from MSA-affected brain. The same antibodies protect cultured neurons from alpha-synuclein toxicity and spreading (propagation).

MSA is a rare, progressive disorder caused by loss of nerve cells in the brain; it affects approximately15,000 people in the United States. Scientific studies indicate that toxic oligomers and small soluble fibrils, derived from naturally occurring alpha-synuclein, are a root cause of disease development and progression in MSA. No disease-modifying treatments exist in part because traditional drug development methods are unable to generate antibodies that can target with precision the neurotoxic forms of alpha-synuclein. The ProMIS platform is a novel, proprietary method for discovering and developing antibodies that can uniquely and precisely target highly toxic misfolded proteins, also called toxic oligomers or prions, while preserving normal forms of the protein and normal protein function. The platform not only generates high-quality antibody candidates but also delivers powerful, validated candidates in months versus years.

“Once again, the ProMIS platform has demonstrated its unique ability to generate antibody candidates with the desired selectivity for toxic misfolded proteins and do so rapidly and cost-effectively,” said Johanne Kaplan, Chief Development Officer at ProMIS Neurosciences. “As new biomarkers for neurodegenerative diseases continue to emerge, the opportunity to advance—with confidence—potential therapies for these diseases is unprecedented. We’ll continue to strengthen our existing programs, while continuing to discover and develop root cause therapies for the many protein misfolding diseases that have stymied the drug development community for decades.”

ProMIS’ new antibody candidates for MSA join a robust pipeline of antibody candidates that demonstrate selectivity for the toxic species arising from naturally occurring proteins in the brain. The pipeline includes:

Alzheimer’s disease:

PMN310, an antibody clinical candidate that demonstrates best-in-class selectivity for the toxic oligomeric form of amyloid beta compared with other antibodies in development.
Potential antibody candidates that selectively target the toxic form of tau
Parkinson’s disease

Antibody candidates showing best-in-class selectivity for toxic forms of alpha- synuclein compared to other therapeutic antibodies in development
ALS (amyotrophic lateral sclerosis)

Antibody candidates selectively targeting toxic forms of TDP43
Antibody candidates selectively targeting toxic forms of SOD1
To learn more about MSA, Alzheimer’s and Parkinson’s diseases, new research supporting therapy development and the promise of new biomarkers, listen to the podcast, Saving Minds, at iTunes or Spotify.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn



For media inquiries, please contact:

Shanti Skiffington

[e-mail]

Tel. [phone]



For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

[e-mail]

Tel. [phone]



The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise

[noretreat]

ProMIS near-term goal is partnering in 3-12 months. The current presentation is here:

https://promisneurosciences.com/wp-content/uploads/2019/09/ProMIS.-Corporate.OV_.-HCW.2019-1.pdf

[noretreat]

Yes ... should be an update on clinical plans soon.

[Phoenix300]

Someone taking a position perhaps. Conference next week I believe.

[noretreat]

One day rally

[Phoenix300]

Interesting.................

[noretreat]

should be the 3rd highest volume day in the past year.

[Phoenix300]

Up 20% intraday

[noretreat]

It is time for an update on clinical progress.

[Phoenix300]

ProMIS Neurosciences to Present at HC Wainwright Investor Conference

Company to showcase its innovative Alzheimer’s, Parkinson’s and ALS programs

TORONTO, Ontario and CAMBRIDGE, Mass. —September 3, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC. The conference is being held September 8-10, 2019 at the New York Palace Hotel in New York.

ProMIS’ Executive Chairman, Eugene Williams will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis) Tuesday, September 10th at 10:25 am ET. The audio webcast and slides of Mr. Williams’ presentation will be archived and available on ProMIS’ web site and through the following link http://wsw.com/webcast/hcw5/arfxf/.

[Phoenix300]

Is that a little end of day buying I spotted ...

Could take off any day, week, month.

[noretreat]

ProMIS Neurosciences Announces Second Quarter 2019 Results
PR NEWSWIRE 6:30 AM ET 8/13/2019

Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease

TORONTO and CAMBRIDGE, MA, Aug. 13, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc.(ARFXF) , a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2019.

"Over the course of the first half of 2019, the breadth and depth of our unique discovery and development platform was further evidenced as ProMIS made considerable progress in expanding its portfolio of opportunities in neurodegenerative diseases," stated Eugene Williams, ProMIS' Executive Chairman. "In the second quarter of this year, we were able to identify novel antibodies for Alzheimer's disease (AD) with selectivity for the neurotoxic form of tau. This is in addition to the prior identification of antibody candidates selectively targeting toxic forms of alpha-synuclein (a-syn) for Parkinson's disease (PD) and toxic, aggregated forms of TDP43 for amyotrophic lateral sclerosis (ALS)."

Corporate Highlights

In June 2019, the Company completed a private placement of 4,680,000 common share units at a price of $0.25 per unit resulting in gross proceeds of approximately $1,170,000 ($1,093,492 net of share issuance costs). Each unit consisted of one common share and one common share warrant. The common shares are subject to a four-month hold period from the date of issuance. Each warrant is exercisable into one common share at a price of $0.35 per share at any time for five years.


In May 2019, ProMIS announced the identification of novel antibodies for AD with selectivity for the neurotoxic form of tau. ProMIS leveraged its proprietary drug discovery and development platform to identify several novel antibodies that selectively bind toxic oligomers of tau. The platform produced antibodies that meet a key success factor for a viable Alzheimer's disease therapy: the ability to selectively target the neurotoxic form of a protein, while sparing the normal forms of the protein, a challenge that has contributed to recent late-stage clinical trial failures. The platform not only generates high-quality antibody candidates, it delivers powerful, validated candidates in months versus years. Used in combination with new biomarkers for Alzheimer's disease, researchers could dramatically improve the success and speed of future therapy development efforts.


In June 2019, ProMIS presented key data on monoclonal antibody PMN310 for AD at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world's most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care. ProMIS Chief Development Officer Dr. Johanne Kaplan presented data showing that PMN310 possesses superior selectivity for amyloid beta toxic oligomers and improved therapeutic potential compared with other amyloid beta-directed antibodies.


Scientific Advisory Board Appointment

In June 2019, the Company appointed C. Warren Olanow, MD, FRCPC, FAAN, FRCP(Hon) to its scientific advisory board (SAB). Dr. Olanow has dedicated his career to the study of neurodegeneration, particularly Parkinson's disease, through his work in academia, scientific research, clinical trials and professional societies. He is the previous Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology at the Mount Sinai School of Medicine in New York City and is presently Professor Emeritus in the Department of Neurology and in the Department of Neuroscience. He also serves as Chief Executive Officer of CLINTREX, a pharmaceutical advisory firm that has designed numerous clinical trials in neurodegenerative disease for the pharmaceutical industry.

Financial Results

Results of Operations – Three months ended June 30, 2019 and 2018

Net loss for the three months ended June 30, 2019 was $1,858,530, compared to a net loss of $2,214,861 for the three months ended June 30, 2018, respectively. Included in the net loss amount for the three months ended June 30, 2019 were non-cash expenses of $153,461, representing share-based compensation and amortization of an intangible asset, compared to $173,544 for the three months ended June 30, 2018. The decrease in the net loss in the three months ended June 30, 2019 reflects a decrease in costs associated with external contract research organizations for internal programs, patent costs and share-based compensation offset by increased consultant salaries and associated costs and general corporate expenditures.

Research and development expenses for the three months ended June 30, 2019 were $1,042,618, as compared to $1,531,075 in the three months ended June 30, 2018. The decrease in research and development expense for the three months ended June 30, 2019 is primarily attributed to decreased costs associated external contract research organizations for internal programs and patent costs offset by higher contracted research salaries and associated costs, and higher share-based compensation.

General and administrative expenses for the three months ended June 30, 2019 were $815,937, as compared to $683,786 in the three months ended June 30, 2018. The increase in general and administrative expense for the three months ended June 30, 2019 is primarily attributable to increased consultant salaries and associated costs and general corporate expenditures offset by decreased share-based compensation.

Results of Operations – Six months ended June 30, 2019 and 2018

Net loss for the six months ended June 30, 2019 was $4,305,107, compared to a net loss of $3,771,733 for the six months ended June 30, 2018, respectively. Included in the net loss amount for the six months ended June 30, 2019 were non-cash expenses of $417,334, representing share-based compensation and amortization of an intangible asset, compared to $502,555 for the six months ended June 30, 2018. The increase in the net loss in the six months ended June 30, 2019 reflects the costs associated with operating the Company's AD therapeutics program, increased contracted research and consultant salaries and associated costs and general corporate expenditures.

Research and development expenses for the six months ended June 30, 2019 were $2,813,271, as compared to $2,229,082 in the six months ended June 30, 2018. The increase in research and development expense for the six months ended June 30, 2019 is primarily attributed to increased spending on external contract research organizations for internal programs, higher contracted research salaries and associated costs, and higher share-based compensation offset by reduced patent costs.

General and administrative expenses for the six months ended June 30, 2019 were $1,491,861, as compared to $1,542,656 in the six months ended June 30, 2018. The decrease in general and administrative expense for the six months ended June 30, 2019 is primarily attributable to decreased share-based compensation offset by increased consultant salaries and associated costs, general corporate expenditures and foreign exchange.

Outlook

The Company will continue to build on its unique, proprietary discovery and development platform to further characterize the potential benefits of its programs selectively targeting toxic aggregates of TDP43 and SOD1 in ALS, toxic forms of a-syn in PD and other a-syn-related disorders, and toxic forms of tau and amyloid beta in AD and other dementias to further support ongoing pharmaceutical partnering discussions.

About ProMIS Neurosciences, Inc.(ARFXF)

ProMIS Neurosciences, Inc. (ARFXF) is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Company documents relating to the fiscal year 2018 annual report and fiscal year 2019 quarterly reports can be viewed on the System for Electronic Document Analysis and Retrieval (SEDAR) at the link below:

https://www.sedar.com/search/search_en.htm

Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn

[Phoenix300]

PR—> https://promisneurosciences.com/video/dr-james-kupiecs-update-from-aaic-2019-demonstrating-early-proof-of-concept-with-biomarkers-and-focused-patient-populations/

[Phoenix300]

If a few more buyers show up this could move even stronger but the trend is great.

[noretreat]

I like the trend

[Phoenix300]

Anyone want to take out those .19’s and the man comes the .20’s

[Phoenix300]

The Bill Gates announcement is a bigger deal than some might suspect. He is stepping in and now many other organizations could very well follow his lead. ARFXF will be a candidate for such opportunity with their novel targeted drug and the need for funds to push this forward faster.

It wouldn’t surprise me to see an announcement of funding within 45 days.

This is very likely even more so on multiple wealthy billionaire’s Foundation’s radar!!

The IND should be getting closer.

Could reach .25 and pause for news, or maybe move up still.

[Phoenix300]

The big news today is Bill Gates giving money towards Alzheimer’s research.

It's hard to overstate how important finding a better diagnostic is for fighting #Alzheimers. That’s why I’m investing in new ideas for easier and more accurate diagnosis of the disease. https://t.co/WM9phNmyJo

— Bill Gates (@BillGates) July 29, 2019

It's hard to overstate how important finding a better diagnostic is for fighting #Alzheimers. That’s why I’m investing in new ideas for easier and more accurate diagnosis of the disease.

Article he had linked in his tweet

Alzheimer's Biomarkers Move Ahead In Research : Shots - Health News : NPR

https://www.npr.org/sections/health-shots/2019/07/04/738478841/new-markers-for-alzheimers-disease-could-aid-diagnosis-and-speed-up-drug-develop

[noretreat]

Love the slow climb. An IND meeting can't be too far out....can it? Still trading only about $50k per day though. Would love to see a pop that doubles it...

[noretreat]

I recently doubled but could not resist some of those 16's today so I added another 15k.

This could be acquired for a few bucks....

[Phoenix300]

Moving up. Added a few more.

[noretreat]

good timing because I just doubled my position in the .14's

[Phoenix300]

Something seems to be cooking

[barnovage]

Management talked about an IND yet? Sorry I still got this on the back burner. Been in other things.

[noretreat]

yes. something is going to happen here by year-end...IND or better.

Not sure if this is the bottom but it has to be close.

[Phoenix300]

Added today.

[Phoenix300]

ProMIS Neurosciences to Present Data at 2019 Alzheimer’s Association International Conference
By Promis Neuro Admin on Jul 10, 2019 07:30 am
Abstracts selected for oral and poster presentation

TORONTO, Ontario and CAMBRIDGE, Mass. —July 10, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give an oral presentation on its lead clinical candidate, PMN310 for Alzheimer’s disease, at the annual Alzheimer’s Association International Conference® (AAIC), which occurs July 14-18. A second poster presentation focuses on the behavior of misfolded TDP43 involved in the development of neurological disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

AAIC® is the largest, most influential international meeting focused on advancing dementia science. The annual conference convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries supporting new methods of prevention, treatment and diagnosis of Alzheimer’s disease.

ProMIS’ Chief Development Officer Dr. Johanne Kaplan will deliver the oral presentation, “Selective Targeting of Amyloid-Beta Oligomer Species By PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency in Alzheimer’s Disease,” on Thursday, July 18, 2019 from 11:45 AM – 12:00 PM in Concourse Hall 151. Dr. Kaplan’s slide presentation will be available on the company’s website immediately following the presentation.

ProMIS’ Chief Science Officer Dr. Neil Cashman will deliver the poster (#33496), “The Pathological Interactome of Tdp-43 Includes Human Wildtype SOD1” on Wednesday, July 17, 2019 in South Hall GH.

The conference takes place at the Los Angeles Convention Center. For more information, visit www.alz.org/aaic.

About the ProMIS Pipeline

ProMIS Neurosciences’ lead candidate, PMN310, is a monoclonal antibody for Alzheimer’s disease created with the ProMIS drug discovery and development platform, a novel, proprietary method for discovering and developing antibodies that can uniquely and precisely target toxic forms of otherwise normal proteins. PMN310 selectively targets the toxic oligomeric species of amyloid beta (Aß), a root cause of Alzheimer’s disease. Preclinical studies show PMN310 demonstrates a high degree of binding to toxic oligomers without binding to non-toxic forms of amyloid beta protein and greater selectivity versus other Aß-directed antibodies. ProMIS has developed antibody candidates that demonstrate high selectivity for the toxic species of naturally occurring proteins in the brain, including other antibody candidates for Alzheimer’s disease that selectively target toxic Tau, antibody candidates for Parkinson’s disease that show best-in-class selectivity for toxic forms of alpha-synuclein, and antibody candidates for ALS that target the toxic form of TDP43.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

[noretreat]

Perhaps the 15 cent trades represent capitulation.

[noretreat]

Some folks seem to be abandoning ship...we shall see if this becomes an opportunity.

[noretreat]

I like “not for distribution to the US....”

[Phoenix300]

Probably closing a deal, and needed enough money to take them through that or those negotiations.

[noretreat]

ProMIS Neurosciences Closing Private Placement
CANADA NEWSWIRE 6:30 AM ET 6/26/2019

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TORONTO, June 26, 2019 /CNW/ - ProMIS Neurosciences, Inc.(ARFXF) , a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that it is closing today a private placement of 4,680,000 units (the "Units") at a price of CDN$0.25 (or US$0.1875) per Unit (the "Offering Price") for gross proceeds of approximately CDN$1,170,000 (the "Offering").

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

"We are pleased with the completion of this private placement", stated Dr. Elliot Goldstein, ProMIS President and CEO. "The additional funds coupled with our conservative expenditure management support a cash runway into late 2019."

Each Unit consists of one common share of the Company (each a "Share") and one share purchase warrant of the Company (each a "Warrant"). Each Warrant entitles the holder thereof to purchase one Share ("a "Warrant Share") at an exercise price of $0.35 per Warrant Share at any time for five years.

All securities issued in connection with the Offering will be subject to a four-month statutory hold period in accordance with applicable securities laws. Net proceeds from the Offering are intended to be used for working capital and general corporate purposes. Closing of the Offering is subject to TSX approval.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About ProMIS Neurosciences Inc.(ARFXF)

ProMIS Neurosciences, Inc. (ARFXF) is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn

[Phoenix300]

Ready for another move up here. Check out MRKR today.

[Phoenix300]

https://promisneurosciences.com/wp-content/uploads/2019/06/The-Future-of-RD-in-Alzheimers-Disease-ProMIS-Neurosciences.pdf

The Future of R&D
in Alzheimer’s
Disease
New investigational drugs with high selectivity for amyloid-ß oligomers and the use of pharmacodynamic biomarkers in Phase 1 trials to enable early go/no-go decisions are changing the R&D landscape

[Phoenix300]

New investors—-> https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2019/PMNTO-PD--ALS-Partnerships-May-Fund-PMN310-Trial-article/default.aspx

[Phoenix300]

Meeting with the FDA to discuss the IND will start to move it and then the IND. Then P1 1sr qtr next year. Notwithstanding they make a deal or get something else with an outside party.

[pennymonster1]

They have had steady news flow in recent months. Hasn’t helped stock by good to see

[Phoenix300]

ProMIS Neurosciences Presents Lead Program for Alzheimer’s Disease at Prestigious Keystone Symposia Scientific Conference
June 5, 2019 News
Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer’s disease among world’s leading researchers
TORONTO, Ontario and CAMBRIDGE, Mass. —June 5, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present key data on monoclonal antibody PMN310 for Alzheimer’s disease at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world’s most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care. ProMIS’ Chief Development Officer Dr. Johanne Kaplan will present the company’s lead therapeutic candidate PMN310 which demonstrates high selectivity for the toxic forms of amyloid beta implicated as a root cause of Alzheimer’s disease.
In the poster, “Selective targeting of HHQK conformational epitope in amyloid-beta oligomer species by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer’s disease,” Dr. Kaplan will present data for PMN310 that show:
Superior selectivity for amyloid beta (AßOs) toxic oligomers.
Potential to safely administer high doses of PMN310 with a reduced risk of brain swelling or ARIA.
Potential to show greater therapeutic potency compared with other Aß-directed antibodies.
“Evidence continues to mount, showing that amyloid-beta toxic oligomers (AßO) – not amyloid plaque – are the key target for Alzheimer’s disease therapy,” said Dr. Johanne Kaplan. “The current therapeutic gap lies in how to effectively neutralize the toxic oligomer without wasting antibody on non-toxic forms of the protein. We’re pleased our data will help inform discussions regarding future directions among the world’s most accomplished researchers. Our data will demonstrate the unique ability of the ProMIS discovery platform to generate antibodies that bind the toxic species of amyloid beta while preserving healthy forms of the protein. Humanized PMN310 is currently in advanced preclinical development.”
The conference, Keystone Symposia on Molecular and Cellular Biology, Neurodegenerative Diseases: New Insights and Therapeutic Opportunities, takes place on June 16-20, 2019 at Keystone Resort in Keystone, Colorado. For more information, please visit www.keystonesymposia.org.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn and listen to the podcast, Saving Minds, at iTunes or Spotify.